4.7 (635) In stock
When used in a treat-to-target approach, therapies for mucosal healing may favorably modify the natural history of inflammatory bowel disease (IBD), reducing the need for steroids and risk of hospitalization.
NEPC20 AGENDA – Connecticut Pharmacists Association
Dr. Edward V. Loftus, MD, Rochester, MN, Gastroenterologist
Son los productos biológicos los indicados para usted?
Son los productos biológicos los indicados para usted?
Satellite Symposia - DDW
Understanding the clinical significance of disease detected by imaging but not by ileoscopy or biopsy - Mayo Clinic
NEPC20 AGENDA – Connecticut Pharmacists Association
specialized ibd, SAVE 16%
Advances in the treatment of Crohn's disease and ulcerative colitis - Mayo Clinic
VMS BioMarketing on LinkedIn: UCB's Bimekizumab is Now Available
Dr. Edward V. Loftus, MD, Rochester, MN, Gastroenterologist
